This board has been quiet...

Discussion in 'Romark' started by anonymous, Nov 28, 2019 at 7:15 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Not much activity here recently. Have things improved at Romark or is it the same old sh!tstorm?
     

  2. anonymous

    anonymous Guest

    I tend to find the pharma companies with the least activity on cafepharma are those who have the least to complain about (with the exception of company size, of course).
    This is a good thing. Seems most people are happy which is why I accepted the job.
     
  3. anonymous

    anonymous Guest

    Quiet no more: just released in journal “Nature”:

    Nitazoxanide, a commercial antiprotozoal agent with an antiviral potential against a broad range of viruses including human and animal coronaviruses, inhibited the 2019-nCoV at a low-micromolar concentration (EC50 = 2.12 μM; CC50 > 35.53 μM; SI > 16.76). Further in vivo evaluation of this drug against 2019-nCoV infection is recommended.
     
  4. anonymous

    anonymous Guest

    Chloroquine might also work. Any drug interaction or cross-toxicity?
     
  5. anonymous

    anonymous Guest

    That could be your ready-to-use cocktail.
     
  6. anonymous

    anonymous Guest

    Well, Gilead’s Remdesivir literally brought the Seattle patient back from the dead, but Gilead is using most of its stock in the China trial. So, availability is going to be a problem. Also, these drugs must be given in a cocktail or resistance develops. So, probably three MOA’s would be best.

    I know that chloroquine was part of one trial.
     
  7. anonymous

    anonymous Guest